|4/AAug 29, 5:51 PM ET

Gitman Paul 4/A

4/A · BIOSPECIFICS TECHNOLOGIES CORP · Filed Aug 29, 2018

Insider Transaction Report

Form 4/AAmended
Period: 2018-08-23
Gitman Paul
Director
Transactions
  • Sale

    Common Stock, $0.001 par value

    2018-08-23$51.27/sh5,425$278,16646,400 total
  • Sale

    Common Stock, $0.001 par value

    2018-08-24$51.09/sh6,400$326,96240,000 total
Footnotes (2)
  • [F1]The selling price of $51.2748 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $50.25 to $52.445. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. This amendment is being provided to report the price range of the transactions in connection with the weighted average sale price reported on this line.
  • [F2]The selling price of $51.0878 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $50.24 to $51.52. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. This amendment is being provided to report the price range of the transactions in connection with the weighted average sale price reported on this line.

Documents

1 file
  • 4
    form4a.xml

    AMENDED STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES